PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin

Low-Back Pain Clinical Trial

— PRO  

Official title:

Patient-reported-outcomes(PROs) in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin in Primary Care Settings

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02273908
• Other study ID #: A0081333
• Status: Completed
• Start date: July 2014
• Est. completion date: March 2015

Study information

• Verified date: October 2016
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic low back pain patients with accompanying lower limb pain (neuropathic component) treated in primary care settings under routine clinical practice.

Description:

Rational and background :

The care for low back pain associated with neuropathic pain is a problem often encountered in daily outpatient.

And the care effectiveness has been frequently evaluated by the patients directly, because the pain would be felt by patients themselves.

On the view of those, we decided to investigate the clinical treatment outcome of pregabalin or other analgesics medication for relief of pain and improvement of sleep interference and QOLs by Patient-reported outcomes.

Research question and objectives :

To evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic low back pain patients with accompanying lower limb pain (neuropathic component) treated in primary care settings under routine clinical practice.

Study design:

This is an 8-week, multicenter prospective observational study. Subjects who have chronic low back pain patients with accompanying lower limb pain (with a neuropathic component) and meet all other entry criteria are enrolled at baseline in the duration of study. The analgesic treatment is determined by the clinical judgment of the physician in charge of patient management. This therapeutic choice is not related to the decision to take part in the study. All enrolled subjects will be received with analgesic treatment. The study requires 3 visits at least, baseline/enrollment visit, Week 4 visit and Week 8 visit (or discontinuation).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 331
• Est. completion date: March 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject who received the enough study information and signed informed consent form.

2. Subject who had chronic low back pain accompanying with lower limb pain from the knee to the ankle.

3. Subject is male or female patient =18 years old.

4. Subject who has complained low back pain for 3 months or more before Visit 1.

5. Subject who is refractory to prior analgesics for 3 months and more.

6. Subject who is able and willing to complete all study related assessment and comply with the study schedule and clinical procedures at clinic.

7. Subject whose pain Numeric Rating Scale(NRS) = 5 at baseline (based on recall over the past week)

Exclusion Criteria:

1. Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason.

2. Subject who has been already treated by pregabalin

Related Conditions & MeSH terms

• Back Pain
• Low Back Pain
• Low-Back Pain

Intervention

Other:
• No intervention
The study is observational

Locations

Country	Name	City	State
Japan	Nakaicho Clinic	Adachi	Tokyo
Japan	Ageo Medical Clinic	Ageo	Saitama
Japan	Mitsuda Orthopaedic Clinic	Chiyoda	Tokyo
Japan	Kyobashi Orthopaedic Clinic	Chuo	Tokyo
Japan	Morishima Clinic	Edogawa	Tokyo
Japan	Arai Orthopaedic Clinic	Fujimino	Saitama
Japan	Jin Orthopaedic Clinic	Ichikawa	Chiba
Japan	Satoh Orthopaedic Clinic	Ichikawa	Chiba
Japan	Shiraishi Orthopaedic Clinic	Ichikawa	Chiba
Japan	Nakamura Orthopaedic Clinic	Kagoshima
Japan	Showa-kai Clinic	Kagoshima
Japan	Kanazawa Hospital	Kanazawa	Yokohama
Japan	Ota General Hospital	Kawasaki	Kanagawa
Japan	Kita Akabane Orthopaedic Clinic	Kita	Tokyo
Japan	Takeuchi Orthopaedic Clinic	Kita	Tokyo
Japan	Tanaka Orthopaedic Clinic	Koganei	Tokyo
Japan	Araki Clinic	Koto	Tokyo
Japan	Kohsei Chuo General Hospital	Meguro	Tokyo
Japan	Meguro Seikeigeka Naika	Meguro	Tokyo
Japan	Meguro Yuai Clinic	Meguro	Tokyo
Japan	Clinic Ushitani	Miyazaki
Japan	Kohnan Matsumoto Orthopaedic Clinic	Miyazaki
Japan	Kimura Clinic	Nagoya	Aichi
Japan	Takemoto Orthopaedic Clinic	Ohta	Tokyo
Japan	Aoki Orthpaedic Clinic	Sagamihara	Kanagawa
Japan	Iwasaki Orthopaedic Clinic	Saitama
Japan	Shiotani Pain Clinic	Shinagawa	Tokyo
Japan	Daido Hospital	Toshima	Tokyo
Japan	Senkawa Shinoda Orthopaedic Clinic	Toshima	Tokyo
Japan	Takahashi Orthopaedic Clinic	Toshima	Tokyo
Japan	Katayama Orthopaedic Memorial Hospital	Tsurumi	Yokohama
Japan	Hiyoshi Hocho Clinic	Yokohama	Kanagawa
Japan	Yamamoto Memorial Hospital	Yokohama	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Taguchi T, Igarashi A, Watt S, Parsons B, Sadosky A, Nozawa K, Hayakawa K, Yoshiyama T, Ebata N, Fujii K. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventiona — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Patients With Adverse Events		Visit2(week4),Final Visit(Week8 or discontinuation)
Primary	Change From Baseline in Pain Related Sleep Interference Scale (PRSIS - Past Week Recall)	The Pain Related Sleep Interference Scale (past week recall) consists of an 11-point rating scale ranging from 0 (pain did not interfere with sleep) to 10 (pain completely interfered with sleep). Change the rating scale from baseline to week 8 in each group. Subjects are to describe how their pain has interfered with their sleep during the past week by choosing the appropriate number between 0 and 10.	Baseline, Final Visit (Week 8)
Secondary	Change From Baseline in Roland Morris Disability Questionnaire (RMDQ)-Total Score-	The RMDQ is an index of how well patients with low back pain are able to function with regard to daily activities. The score for the index ranges from 0 to 24 with a lower score indicating better function.	Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)
Secondary	Change From Baseline in Roland Morris Disability Questionnaire (RMDQ)-Japanese Standardized Score-	The RMDQ is an index of how well patients with low back pain are able to function with regard to daily activities. The score for the index ranges from 0 to 24 with a lower score indicating better function.	Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)
Secondary	Change From Baseline in Pain Numeric Rating Scale (Pain NRS - Past Week Recall)	The Pain NRS (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain). Subjects are asked to describe their average pain during the past week by choosing the appropriate number between 0 and 10.	Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)
Secondary	Change From Baseline in Euro Qol 5-Dimensions (EQ-5D-5L)-QOL-Score-	The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. The Health State Profile is designed to record the subject's level of current health for five domains comprising a health profile: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Responses from the five domains are used to calculate a single utility index value.; 1 indicates better health state (no problems); 5 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile; from 11111 to 55555. Score is transformed and results in a total score range -0.025 to 1.000; higher score indicates a better health state.	Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)
Secondary	Change From Baseline in Euro Qol 5-Dimensions (EQ-5D-5L)-Visual Analogue Scale -	The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. There are two components to the EQ-5D-5L: A Health State Profile and a Visual Analogue Scale (VAS). Recent guidance suggests that the Health State Profile and VAS should be administered together.; The Visual Analogue Scale (VAS) is designed to rate the subject's current health state on a scale from 0 to 100 where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.	Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)
Secondary	Clinical Global Impression of Change (CGIC)	The CGIC assessment includes one question (1-7 scale) inquiring about the subject's improvement considering their current disease state.; range from 1 (very much improved) to 7 (very much worse).	Final Visit (Week8 or discontinuation)
Secondary	Patient Global Improvement of Change (PGIC)	The PGIC is a subject-rated instrument that measures change in the subject's overall status on a 7-point scale. Scores range from 1 (very much improved) to 7 (very much worse).	Final Visit (Week8 or discontinuation)
Secondary	Work Productivity and Activity Impairment Scale (WPAI:LBP)	The WPAI: LBP is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Subscale scores include Percent work time missed due to pain (PWP), Percent overall work impairment (PWI), Percent work productivity impairment due to pain (PWPI), Percent overall activity impairment (PAI). Each subscale score is expressed as an impairment percentage (0-100) where higher numbers indicate greater impairment and less productivity. Here, "n" signifies "Number of participants" for Baseline.; In this study, the WPAI: LBP will measure the effect of the patient's Chronic Low Back Pain (CLBP) with accompanying lower limb pain (neuropathic component) on work productivity and regular activities.	Final Visit (Week8 or discontinuation)